Emerging role of immune therapy in treatment of neurodegenerative diseases

Research Article
Open access

Emerging role of immune therapy in treatment of neurodegenerative diseases

Jiaxi Zhao 1*
  • 1 Wuhan University    
  • *corresponding author 2020302041012@whu.edu.cn
Published on 20 December 2023 | https://doi.org/10.54254/2753-8818/22/20230927
TNS Vol.22
ISSN (Print): 2753-8826
ISSN (Online): 2753-8818
ISBN (Print): 978-1-83558-217-6
ISBN (Online): 978-1-83558-218-3

Abstract

Neurodegenerative disorders, a category of illnesses that develop as neurons gradually become defective and eventually die, including Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). Slowly progressing neurodegenerative disorders are accompanied by cognitive decline and functional impairment, significantly burdening individuals and society. At present, clinical treatment is still mainly symptomatic support. The incidence rate has been rising in recent years, and there is a trend toward younger age, which has a negative impact on people's physical health and quality of life. The worldwide burden will continue to increase as the population of the elderly grows, with latent impacts due to prolonged disease durations and changing environments. Unfortunately, such disorders are still untreated because of their complicated pathophysiology. The primary goals of current therapies are to reduce disease symptoms and halt disease progression. Pre-clinical studies for therapeutic methods for AD, PD, and HD have shown promise for AAV intraparenchymal injections and cerebrospinal fluid (CSF) delivery. While CRISPR/Cas9-mediated approaches have been employed to develop disease models, identify pathogenic genes, elucidate pathogenesis mechanisms, and as a potential therapeutic approach. This review not only systematically introduces the current situation and diffuse subsets of neurodegenerative diseases, but also discusses treatments for neurodegenerative diseases.

Keywords:

neurodegenerative diseases, therapy, Alzheimer's disease, Parkinson's disease, Huntington's disease

Zhao,J. (2023). Emerging role of immune therapy in treatment of neurodegenerative diseases. Theoretical and Natural Science,22,25-31.
Export citation

References

[1]. LI Ying, QIAN Meiqi, QIU Xue. Biomarkers and new technologies for early diagnosis of Alzheimer's disease[J]. Journal of Analysis and Testing,2022,41(04):553-561.

[2]. Filippo Baldacci, Simone Lista, Francesco Garaci, Ubaldo Bonuccelli, Nicola Toschi, Harald Hampel. Classification of neurodegenerative diseases guided by biomarkers[J]. Journal of Sport and Health Science,2016,5(04):383-387+511.

[3]. SUN Xuelian,DENG Yiping,DONG Birong. Brief analysis of the progress of dementia and Alzheimer's disease[J]. Modern Clinical Medicine,2022,48(04):310-313.

[4]. HE Guannan. Onset and prevention of Alzheimer's disease under the aging trend in China[J]. Electronic Journal of Clinical Medical Literature,2016,3(40):8083-8084.

[5]. LAI Lanmei,LING Cuixia,ZHANG Xiangfei,HU Chunhua. Research progress on the pathog-enesis of Alzheimer's disease[J]. Journal of Shangqiu Normal University,2018,34(12):27-29.

[6]. ZHANG Lei,FAN Zhanfang,ZHANG Zuopeng,CHENG Yingsheng,LIU Yang. Research progress on pathogenesis and related therapeutic drugs for Alzheimer's disease[J]. Chinese Journal of Medicinal Chemistry,2021,31(06):438-446+469.

[7]. Heben. United States:Fruit consumption may reduce the chance of Alzheimer's disease[J].China Fruit Information,2023,40(04):54.

[8]. ZHANG Zhenxin. Diagnosis of Parkinson's disease[J]. Chinese Journal of Neurology,2006(0-6):408-409.

[9]. PANG Wenyuan,ZHAI Lijie,LIU Yilin,CHEN Xinwei,ZHU Bin,LI Jing,JIN Yan,ZHAO Zhigang. Chinese Journal of Clinical Pharmacology,2022,38(21):2638-2643.

[10]. WANG Xijin,ZHANG Yu,CHEN Shengdi. Ten years of research on the pathogenesis and tr-eatment of Parkinson's disease[J]. Chinese Journal of Modern Neurological Diseases,2010,10(01):36-42.

[11]. ZHAO Qianhua,GUO Qihao,HONG Zhen. Aducanumab treatment reduces β amyloid deposi-tion in the brain of patients with Alzheimer's disease[J]. Chinese Journal of Clinical Ne-uroscience,2017,25(01):61-64.

[12]. CHEN Zisheng, LUO Huanmin. Cholinergic therapy for Alzheimer's disease[J]. China Journal of New Drugs,2001(06):415-419.

[13]. Yingquan Wang, Jinghong Liang, Ruixia Jia, Yong Xu.Prediction of Alzheimer's disease in China from 2020 to 2050[J].Alzheimer's disease and related diseases,2019,2(01):289-298.

[14]. ZHANG Kun,GUO Ruichen. Study on mechanism of action, in vivo process and measurement technology of memantine hydrochloride[J].Qilu Pharmaceutical Affairs,2008(10):610-612.

[15]. CHEN Shengdi. Guidelines for the treatment of Parkinson's disease[J]. Chinese Journal of Neurology,2006(06):409-412.

[16]. ZHANG Zhenxin. Diagnosis of Parkinson's disease[J]. Chinese Journal of Neurology,2006(0-6):408-409.

[17]. LIU Yang,HU Chun. Xenazine[J]. Chinese Journal of Medicinal Chemistry,2009,19(01):80.

[18]. Wu Zhiying. Molecular pathogenesis and treatment progress of Huntington's disease[J]. Journal of Modern Neurological Diseases,2009,9(03):238-241.

[19]. LI Qianqian, XIA Yan, HOU Tiantian, WANG Chao, SHI Qianqian, MA Xuemei, LIU Ziyang, ZHANG Yingli, WU Xiaobing, WANG Sanlong, LIU Guoqing, GENG Xingchao. Preclinical neurological safety evaluation of gene therapy drug AAV5-lipoprotein lipase variant[J]. Chinese Pharmacovigilance,2023,20(01):34-39.

[20]. Janson, C., Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain [J]. Human gene therapy, 2002,13(11), 1391–1412.

[21]. WU Jianrong,ZHENG Ling,GU Yan,WANG Xiaoyu,ZHANG Hongbin. Diagnosis and treatment of retroperitoneal malignant salamander tumor-With two case reports[J]. Sichuan Cancer Prevention and Treatment,2007(03):199-200.

[22]. Rafii, M. S., Baumann, T. L., Bakay, R. A., Ostrove, et al. A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease[J]. Alzheimer's & dementia: the journal of the Alzheimer's Association, 2014,10(5), 571–581.

[23]. LU Lingling,ZHAO Huanying,WU Jun,YANG Hui. Study on a rat model of dopamine synthesis-related enzyme gene combination therapy for Parkinson's disease[J]. Chinese Journal of Biotechnology,2009,29(02):34-41.

[24]. ZHAO Bo,ZHANG Xinyu,FU Xuefeng. Research progress in animal models of Alzheimer's disease[J]. Journal of Neuroanatomy,2012,28(01):102-104.

[25]. HE Jing,WANG Rong. Application of CRISPR/Cas9 gene editing technology in Alzheimer's disease research[J]. Neurological Diseases and Mental Health,2022,22(11):786-792.

[26]. Gong Shaohua, Li Na, Tang Bo. Research progress on regulating CRISPR-Cas9 system for gene editing[J]. Acta Chem Sinica,2020,78(07):634-641.

[27]. ZHU Shaoyi, GUAN Lihong, LIN Juntang. Application of CRISPR-Cas9 system in disease model[J].Chinese Journal of Biotechnology,2016,36(10):79-85.

[28]. TANG Yaning, JI Lina, HUA Zichun. Exploring key genes and pathways affecting Alzheim-er's disease progression based on big data analysis[J]. Pharmaceutical Biotechnology,202-2,29(04):331-337.

[29]. GENG Yunfeng,LI Xiaona,LU Yujuan,JIA Jinguang,YANG Tao. DNAJC6 overexpression can induce epithelial-mesenchymal transition in hepatoma cells[J]. Journal of Hebei Medical University,2017,38(02):151-153+158.

[30]. Ishizu, N., Yui, D., Hebisawa, A., et al. Impaired striatal dopamine release in homozygous Vps35 D620N knock-in mice [J]. Human molecular genetics, 2016,25(20), 4507–4517.

Cite this article

Zhao,J. (2023). Emerging role of immune therapy in treatment of neurodegenerative diseases. Theoretical and Natural Science,22,25-31.

Data availability

The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.

Disclaimer/Publisher's Note

The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of EWA Publishing and/or the editor(s). EWA Publishing and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

About volume

Volume title: Proceedings of the 3rd International Conference on Biological Engineering and Medical Science

ISBN：978-1-83558-217-6(Print) / 978-1-83558-218-3(Online)
Editor：Alan Wang
Conference website: https://www.icbiomed.org/
Conference date: 2 September 2023
Series: Theoretical and Natural Science
Volume number: Vol.22
ISSN：2753-8818(Print) / 2753-8826(Online)

© 2024 by the author(s). Licensee EWA Publishing, Oxford, UK. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open access policy for details).

References

[1]. LI Ying, QIAN Meiqi, QIU Xue. Biomarkers and new technologies for early diagnosis of Alzheimer's disease[J]. Journal of Analysis and Testing,2022,41(04):553-561.

[2]. Filippo Baldacci, Simone Lista, Francesco Garaci, Ubaldo Bonuccelli, Nicola Toschi, Harald Hampel. Classification of neurodegenerative diseases guided by biomarkers[J]. Journal of Sport and Health Science,2016,5(04):383-387+511.

[3]. SUN Xuelian,DENG Yiping,DONG Birong. Brief analysis of the progress of dementia and Alzheimer's disease[J]. Modern Clinical Medicine,2022,48(04):310-313.

[4]. HE Guannan. Onset and prevention of Alzheimer's disease under the aging trend in China[J]. Electronic Journal of Clinical Medical Literature,2016,3(40):8083-8084.

[5]. LAI Lanmei,LING Cuixia,ZHANG Xiangfei,HU Chunhua. Research progress on the pathog-enesis of Alzheimer's disease[J]. Journal of Shangqiu Normal University,2018,34(12):27-29.

[6]. ZHANG Lei,FAN Zhanfang,ZHANG Zuopeng,CHENG Yingsheng,LIU Yang. Research progress on pathogenesis and related therapeutic drugs for Alzheimer's disease[J]. Chinese Journal of Medicinal Chemistry,2021,31(06):438-446+469.

[7]. Heben. United States:Fruit consumption may reduce the chance of Alzheimer's disease[J].China Fruit Information,2023,40(04):54.

[8]. ZHANG Zhenxin. Diagnosis of Parkinson's disease[J]. Chinese Journal of Neurology,2006(0-6):408-409.

[9]. PANG Wenyuan,ZHAI Lijie,LIU Yilin,CHEN Xinwei,ZHU Bin,LI Jing,JIN Yan,ZHAO Zhigang. Chinese Journal of Clinical Pharmacology,2022,38(21):2638-2643.

[10]. WANG Xijin,ZHANG Yu,CHEN Shengdi. Ten years of research on the pathogenesis and tr-eatment of Parkinson's disease[J]. Chinese Journal of Modern Neurological Diseases,2010,10(01):36-42.

[11]. ZHAO Qianhua,GUO Qihao,HONG Zhen. Aducanumab treatment reduces β amyloid deposi-tion in the brain of patients with Alzheimer's disease[J]. Chinese Journal of Clinical Ne-uroscience,2017,25(01):61-64.

[12]. CHEN Zisheng, LUO Huanmin. Cholinergic therapy for Alzheimer's disease[J]. China Journal of New Drugs,2001(06):415-419.

[13]. Yingquan Wang, Jinghong Liang, Ruixia Jia, Yong Xu.Prediction of Alzheimer's disease in China from 2020 to 2050[J].Alzheimer's disease and related diseases,2019,2(01):289-298.

[14]. ZHANG Kun,GUO Ruichen. Study on mechanism of action, in vivo process and measurement technology of memantine hydrochloride[J].Qilu Pharmaceutical Affairs,2008(10):610-612.

[15]. CHEN Shengdi. Guidelines for the treatment of Parkinson's disease[J]. Chinese Journal of Neurology,2006(06):409-412.

[16]. ZHANG Zhenxin. Diagnosis of Parkinson's disease[J]. Chinese Journal of Neurology,2006(0-6):408-409.

[17]. LIU Yang,HU Chun. Xenazine[J]. Chinese Journal of Medicinal Chemistry,2009,19(01):80.

[18]. Wu Zhiying. Molecular pathogenesis and treatment progress of Huntington's disease[J]. Journal of Modern Neurological Diseases,2009,9(03):238-241.

[19]. LI Qianqian, XIA Yan, HOU Tiantian, WANG Chao, SHI Qianqian, MA Xuemei, LIU Ziyang, ZHANG Yingli, WU Xiaobing, WANG Sanlong, LIU Guoqing, GENG Xingchao. Preclinical neurological safety evaluation of gene therapy drug AAV5-lipoprotein lipase variant[J]. Chinese Pharmacovigilance,2023,20(01):34-39.

[20]. Janson, C., Gene therapy of Canavan disease: AAV-2 vector for neurosurgical delivery of aspartoacylase gene (ASPA) to the human brain [J]. Human gene therapy, 2002,13(11), 1391–1412.

[21]. WU Jianrong,ZHENG Ling,GU Yan,WANG Xiaoyu,ZHANG Hongbin. Diagnosis and treatment of retroperitoneal malignant salamander tumor-With two case reports[J]. Sichuan Cancer Prevention and Treatment,2007(03):199-200.

[22]. Rafii, M. S., Baumann, T. L., Bakay, R. A., Ostrove, et al. A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease[J]. Alzheimer's & dementia: the journal of the Alzheimer's Association, 2014,10(5), 571–581.

[23]. LU Lingling,ZHAO Huanying,WU Jun,YANG Hui. Study on a rat model of dopamine synthesis-related enzyme gene combination therapy for Parkinson's disease[J]. Chinese Journal of Biotechnology,2009,29(02):34-41.

[24]. ZHAO Bo,ZHANG Xinyu,FU Xuefeng. Research progress in animal models of Alzheimer's disease[J]. Journal of Neuroanatomy,2012,28(01):102-104.

[25]. HE Jing,WANG Rong. Application of CRISPR/Cas9 gene editing technology in Alzheimer's disease research[J]. Neurological Diseases and Mental Health,2022,22(11):786-792.

[26]. Gong Shaohua, Li Na, Tang Bo. Research progress on regulating CRISPR-Cas9 system for gene editing[J]. Acta Chem Sinica,2020,78(07):634-641.

[27]. ZHU Shaoyi, GUAN Lihong, LIN Juntang. Application of CRISPR-Cas9 system in disease model[J].Chinese Journal of Biotechnology,2016,36(10):79-85.

[28]. TANG Yaning, JI Lina, HUA Zichun. Exploring key genes and pathways affecting Alzheim-er's disease progression based on big data analysis[J]. Pharmaceutical Biotechnology,202-2,29(04):331-337.

[29]. GENG Yunfeng,LI Xiaona,LU Yujuan,JIA Jinguang,YANG Tao. DNAJC6 overexpression can induce epithelial-mesenchymal transition in hepatoma cells[J]. Journal of Hebei Medical University,2017,38(02):151-153+158.

[30]. Ishizu, N., Yui, D., Hebisawa, A., et al. Impaired striatal dopamine release in homozygous Vps35 D620N knock-in mice [J]. Human molecular genetics, 2016,25(20), 4507–4517.

For authors
Guide for authors Policies for authors Aims and scope Subscription Open access policy
For editors
Policies for editors Editorial board
For reviewers
Policies for reviewers Privacy policy

Cookies are used by this site.
Copyright © 2024 EWA Publishing, its licensors, and contributors. All rights reserved, including text and data mining, AI training, and similar technologies.